Washington, DC 20006-5349
HELPLINE
Today, the Mesothelioma Applied Research Foundation announced that it will fund three research projects in the field of mesothelioma for a total investment of $300,000…
At the end of May, in a brand new virtual format, the annual meeting for the American Society of Clinical Oncology (ASCO) was one of…
A new approach of anti-PD1 immunotherapy (atezolizumab) combined with bevacizumab (an agent that blocks the growth of new blood vessels therefore limiting the supply of…
A phase 2 immunotherapy clinical trial combining durvalumab, an immunotherapy drug, with standard treatment of Alimta (pemetrexed)/cisplatin has shown promising overall survival results. The study enrolled 55 patients and…
In 2016, the Mesothelioma Applied Research Foundation funded a grant to Antonio Giordano, MD, PhD, director and founder of the Sbarro Health Research Organization at Temple University, to investigate how silencing…
A white paper documenting presentations and discussions from the Mesothelioma Patient Registry workshop, which was convened by the Mesothelioma Applied Research Foundation in March of…
In late August, the Mesothelioma Applied Research Foundation hosted an interview as part of its Meet the Mesothelioma Experts (MTME) series to discuss a new…
The New York Proton Center, the first proton therapy facility to open in the state of New York, began treating patients at its state-of-the-art East…
On July 24, 2019, the Mesothelioma Applied Research Foundation hosted Michael Harbut, MD, on our Meet the Mesothelioma Experts (MTME) live broadcast, where he discussed…
On Wednesday, July 24, 2019, at 8:00 PM EDT, the Meso Foundation’s Meet the Mesothelioma Experts live broadcast will feature Michael Harbut, MD. Dr. Harbut will…
Get the latest information about mesothelioma, clinical trials, patient stories, community events, and much more!
